About This eGFR Calculator
This eGFR Calculator provides a comprehensive assessment of kidney function by computing the estimated Glomerular Filtration Rate (eGFR) and Creatinine Clearance (CrCl) using four distinct, widely-recognized formulas. It calculates results from the modern CKD-EPI (2021) equation, its predecessor the CKD-EPI (2009), the classic MDRD formula, and the Cockcroft-Gault equation. This allows healthcare professionals to compare results, understand the evolution of GFR estimation, and apply the most appropriate value for their specific clinical scenario, whether for staging chronic kidney disease or for adjusting medication dosages.
The Formulas Explained
CKD-EPI (2021) Equation
The most current and recommended formula, which removes the race coefficient to improve equity in diagnosis. The formula varies by sex and serum creatinine level.
$$\text{eGFR} = 142 \times \min(\frac{S_{cr}}{k}, 1)^\alpha \times \max(\frac{S_{cr}}{k}, 1)^{-1.200} \times 0.9938^\text{Age} \times (\text{1.012 if Female})$$
Where $k$ is 0.7 for females and 0.9 for males, and $\alpha$ is -0.241 for females and -0.302 for males.
Cockcroft-Gault Formula (CrCl)
Estimates creatinine clearance (not eGFR) and is not normalized for body surface area. It requires patient weight.
$$\text{CrCl (mL/min)} = \frac{(140 – \text{Age}) \times \text{Weight (kg)}}{72 \times S_{cr}} \times (\text{0.85 if Female})$$
Clinical Interpretation & Limitations
The eGFR result from the CKD-EPI 2021 equation is used to stage Chronic Kidney Disease (CKD) according to the KDIGO 2024 guideline, which classifies CKD by combined GFR category (G1–G5) and albuminuria category (A1–A3) — the “CGA” staging used in the KDIGO risk heat map. The G1–G5 GFR cutoffs below are unchanged from previous guidance. KDIGO 2024 also recommends confirming GFR with a combined creatinine-plus-cystatin C estimate (eGFRcr-cys) when greater accuracy is needed, such as for drug dosing, transplant eligibility, or when serum creatinine may be unreliable (low muscle mass, frailty, amputation).
- Stage G1: ≥ 90 mL/min/1.73m² (Normal or high)
- Stage G2: 60-89 mL/min/1.73m² (Mildly decreased)
- Stage G3a: 45-59 mL/min/1.73m² (Mildly to moderately decreased)
- Stage G3b: 30-44 mL/min/1.73m² (Moderately to severely decreased)
- Stage G4: 15-29 mL/min/1.73m² (Severely decreased)
- Stage G5: < 15 mL/min/1.73m² (Kidney failure)
Limitations
It is crucial to recognize that these formulas are estimations. Their accuracy is reduced in certain populations, including individuals with extremes in muscle mass or body weight (e.g., amputees, bodybuilders, malnourished patients), those on specific diets (vegetarian, creatine supplements), and in cases of acute kidney injury where serum creatinine is fluctuating.
Frequently Asked Questions (FAQ)
1. Which eGFR formula is the best one to use?
For general clinical use, including diagnosing and staging Chronic Kidney Disease, the CKD-EPI 2021 equation is the most accurate and currently recommended formula. The Cockcroft-Gault formula remains important for drug dosing, as many pharmaceutical guidelines are based on its CrCl values.
2. Why was the race variable removed from the CKD-EPI formula?
The race coefficient was removed because race is a social, not a biological, construct. Its inclusion was based on observations that Black individuals had higher average creatinine levels for a given GFR, but this does not hold true for all individuals and can perpetuate healthcare disparities. The 2021 formula was developed to be equitable without a clinically significant loss in overall accuracy.
3. What is the difference between eGFR and Creatinine Clearance (CrCl)?
eGFR is an estimate of the Glomerular Filtration Rate, which is the rate at which blood is filtered by the kidneys. CrCl is an estimate of the rate at which creatinine is cleared from the body, which includes both filtration and a small amount of active secretion by the kidney tubules. Because of this secretion, CrCl typically overestimates the true GFR slightly.
4. Why is my Cockcroft-Gault result so different from the eGFR results?
There are two main reasons. First, Cockcroft-Gault calculates CrCl (mL/min), while MDRD and CKD-EPI calculate eGFR (mL/min/1.73m²). The eGFR values are normalized to a standard body surface area (BSA) of 1.73m², while C-G is not. In very large or small individuals, this difference can be significant. Second, the formulas were derived from different patient populations using different mathematical models.
5. Can I use this eGFR calculator for children?
No. These formulas are validated for adults only. Estimating GFR in children requires specialized pediatric formulas, such as the Bedside Schwartz equation, which accounts for height and is designed for the pediatric population.
📖 Sources:
- Inker LA, Eneanya ND, Coresh J, et al. (2021). New Creatinine- and Cystatin C–Based eGFR Equations without a Race Coefficient. N Engl J Med, 385:1737-1749. PMID: 34554658.
- KDIGO CKD Work Group. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, 105(4S):S117-S314. PMID: 38490803.
- Delgado C, Baweja M, Crews DC, et al. (2022). A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis, 79(2):268-288. PMID: 34563581.
- Levey AS, Stevens LA, Schmid CH, et al. (2009). A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med, 150(9):604-612. PMID: 19414839.
- Levey, A. S., Bosch, J. P., Lewis, J. B., et al. (1999). A More Accurate Method to Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Annals of Internal Medicine, 130(6), 461-470.
- Cockcroft, D. W., & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron, 16(1), 31-41.
⚠️ Disclaimer:
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context.
